Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Food and Drug Administration (FDA) has approved APP Pharmaceuticals to market Metoprolol Tartrate injection, USP.
Subscribe to our email newsletter
Metoprolol Tartrate injection, USP is the generic equivalent of Lopressor, which is marketed by Novartis International, and is used in the treatment of acute myocardial infarction (AMI).
APP Pharma claimed that Metoprolol Tartrate injection, USP is AP-rated, preservative-free and bar-coded, and is packaged in single dose 5mg/5ml vials.
APP Pharma president and CEO John Ducker said that APP’s approval of Metoprolol Tartrate injection, USP, will provide an affordable, generic treatment for millions of patients who suffer a heart attack or acute myocardial infarction each year, additionally, this approval further expands APP’s growing Critical Care product line.